Stellar Pharmaceuticals gets Uracyst patent in Japan

Stellar Pharmaceuticals (OTCQB:SLXCF) has received a patent from the Japan Patent Office for one of its lead products, Uracyst,  covering the treatment of cystitis and other related conditions by instillation into the bladder of a dose comprising of at least 350 mg in a volume of from 10 ml to 100 ml. The patent will [...]

Watson has high hopes for Stellar’s Uracyst drug

Watson Pharmaceuticals (NYSE:WPI) CEO, Paul Bisaro, painted a rosy picture of how Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug, which is indicated to treat interstitial cystitis, fills out its urology strategy. According to a presentation at a healthcare conference sponsored by Barclays Capital, Mr. Bisaro said that Watson’s strategy is based on the 10 most common [...]